Tavolixizumab (MEDI 0562) is a humanized monoclonal antibody targeting tumor necrosis factor receptor superfamily member 4 (TNFRSF4, OX40), acting as an OX40 agonist to promote T-cell proliferation and activation, with potent anti-tumor immune potential.
Reinheit:
95.00%
CAS Nummer:
[1635395-25-3]
Target-Kategorie:
Immunology/Inflammation related
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten